Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation

Journal of Hepatology

Volumn 67, Issue 6, 2017, Pages 1168-1176

  Pascasio, Juan Manuel ^a   Vinaixa, Carmen ^b   Ferrer, María Teresa ^a   Colmenero, Jordi ^c   Rubin, Angel ^b   Castells, Lluis ^d   Manzano, María Luisa ^e   Lorente, Sara ^f   Testillano, Milagros ^g   Xiol, Xavier ^h   Molina, Esther ⁱ   González Diéguez, Luisa ^j   Otón, Elena ^k   Pascual, Sonia ^l   Santos, Begoña ^d   Herrero, José Ignacio ^m   Salcedo, Magdalena ⁿ   Montero, José Luis ^o   Sánchez Antolín, Gloria ^p   Narváez, Isidoro ^q   Nogueras, Flor ^r   Giráldez, Álvaro ^a   Prieto, Martín ^b   Forns, Xavier ^c   Londoño, María Carlota ^c   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^k HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^m UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^p HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^q HOSPITAL INFANTA CRISTINA   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

more..

Author keywords

Delisting; Direct acting antivirals; Hepatitis C; Liver transplantation; Waiting list

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; BILIRUBIN; BOCEPREVIR; CREATININE; DACLATASVIR; HEMOGLOBIN; LEDIPASVIR; OMBITASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BILIARY TRACT DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COHORT ANALYSIS; COMPENSATED LIVER CIRRHOSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG TOLERABILITY; EPILEPTIC STATE; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; HEART ARREST; HEPATITIS C; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; CLINICAL TRIAL; MIDDLE AGED;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WAITING LISTS;

EID: 85029847992     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.08.008     Document Type: Article

References (28)

1. Crespo, G., Marino, Z., Navasa, M., Forns, X., Viral hepatitis in liver transplantation. Gastroenterology 142 (2012), 1373–1383 e1.
2. Carrion, J.A., Martinez-Bauer, E., Crespo, G., Ramirez, S., Perez-del-Pulgar, S., Garcia-Valdecasas, J.C., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 50 (2009), 719–728.
3. Everson, G.T., Terrault, N.A., Lok, A.S., Rodrigo, D.R., Brown, R.S. Jr., Saab, S., et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology 57 (2013), 1752–1762.
4. Iacobellis, A., Andriulli, A., Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin Pharmacother 10 (2009), 1929–1938.
5. Curry, M.P., Forns, X., Chung, R.T., Terrault, N.A., Brown, R., Fenkel, J.M., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107 e1.
6. Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
7. Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
8. Belli, L.S., Berenguer, M., Cortesi, P.A., Strazzabosco, M., Rockenschaub, S.-R., Martini, S., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 65 (2016), 524–531.
9. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 66 (2017), 153–194.
10. Lencioni, R., Llovet, J., Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 052–60.
11. Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
12. Beste, L.A., Green, P.K., Berry, K., Kogut, M.J., Allison, S.K., Ioannou, G.N., Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 67 (2017), 32–39.
13. Prenner, S.B., VanWagner, L.B., Flamm, S.L., Salem, R., Lewandowski, R.J., Kulik, L., Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 66 (2017), 1173–1181.
14. Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., et al. Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. J Hepatol 57 (2012), 1379–1390.
15. Bunchorntavakul, C., Reddy, K.R., Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 23 (2016), 408–418.
16. Coilly, A., Pageaux, G.-P., Houssel-Debry, P., Duvoux, C., Radenne, S., de Ledinghen, V., et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs?. Hepatology, 62, 2015, 257A.
17. Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Multimer, D., et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.
18. van der Meer, A., Feld, J.J., Hofer, H., Almasio, P.L., Calvaruso, V., Fernández-Rodríguez, C.M., et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 66 (2017), 485–493.
19. Janjua, N., Chong, M., Kuo, M., Woods, R., Wong, J., Yoshida, E.M., et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol 66 (2017), 504–513.
20. Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
21. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
22. Romano, A., Capra, F., Piovesan, S., Chemello, L., Cavalletto, L., Anastassopoulos, G., et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology, 64, 2016, 10A.
23. Yang, J.D., Aqel, B.A., Pungpapong, S., Gores, G.J., Roberts, L.R., Leise, M.D., Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 65 (2016), 859–860.
24. Jonas, S., Bechstein, W.O., Steinmüller, T., Herrmann, M., Radke, C., Berg, T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33 (2001), 1080–1086.
25. Foster, G.R., Irving, W.L., Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
26. Chen, T., Terrault, N.A., Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant 21 (2016), 111–119.
27. de la Rosa, G., Fondevila, C., Navasa, M., Liver transplantation in Spain. Liver Transplant 22 (2016), 1259–1264.
28. Chhatwal, J., Samur, S., Kues, B., Aver, T., Roberts, M., Kanwal, F., et al. Optimal timing of hepatitis C treatment for patients on liver transplant waiting list. Hepatology 65 (2017), 777–788.